Positive results for osimertinib in patients with EGFR-mutated lung cancer

In the Phase III ADAURA trial, adjuvant osimertinib was associated with improved disease-free survival in early-stage EGFR-mutated non-small cell lung cancer, with 89% alive and disease-free at 2 years vs. 53% with placebo. Results will be presented at ASCO.